Dragon Pharma PE 22-28: Potent TREK-1 Channel Inhibitor
For athletes, bodybuilders, and fitness enthusiasts, mental resilience, mood stability, and cognitive function are as critical as physical performance. The demands of intense training, competition preparation, and lifestyle pressures can impact emotional well-being and mental clarity. PE 22-28 is a seven-amino-acid peptide (GVSWGLR) designed as a stable, high-affinity inhibitor of the TREK-1 potassium channel, making it a potent candidate for researching depression, anxiety, and neurogenesis. This Dragon Pharma PE 22-28 10mg offering delivers high-purity lyophilized powder in a sterile 2mL vial, providing researchers with a premium compound for advanced mood, anxiety, and neurogenesis research.
PE 22-28 functions as a selective inhibitor of the TREK-1 (TWIK-related potassium channel-1) channel, which plays a critical role in regulating neuronal excitability and mood. By blocking TREK-1, PE 22-28 promotes neuronal activity and has been shown to produce rapid antidepressant-like effects in research models. It is a shortened analog of the natural peptide spadin, designed for improved bioavailability, stability, and faster onset of action. Research published in the NIH PubMed database demonstrates that PE 22-28 exhibits potent antidepressant and anxiolytic properties, potentially triggering neurogenesis faster than traditional antidepressants. Its unique mechanism of action makes it a valuable tool for research into mood disorders, stress resilience, and neuroplasticity.
The relevance of PE 22-28 to the athletic and bodybuilding community is significant. The psychological demands of training, competition, and recovery can impact mental health. Additionally, hormonal fluctuations associated with training cycles and androgen use can affect mood and emotional well-being. PE 22-28 offers researchers a tool to study neurogenesis, stress resilience, and mood regulation at the molecular level. Its rapid onset of action and potential to promote neuroplasticity make it valuable for research into cognitive recovery, stress adaptation, and emotional resilience. The 10mg vial provides a convenient size for research protocols requiring precise dosing.
Quality assurance is paramount in peptide research. Each batch of our PE 22-28 10 mg inventory undergoes rigorous third-party HPLC-MS testing to verify purity and dosage. Lab test documentation will be available shortly, reflecting Dragon Pharma's commitment to transparency and quality across all products.
For bodybuilders and strength athletes researching mental resilience and cognitive optimization, PE 22-28 offers a unique tool for studying mood regulation and neurogenesis. Its TREK-1 channel inhibitor mechanism provides a distinct pathway from traditional mood-modulating compounds, addressing neuronal excitability and plasticity. Whether investigating strategies for stress resilience, mood stability, or cognitive recovery, Dragon Pharma's PE 22-28 delivers the purity, potency, and reliability required for serious research into neurobiology and mental health.
Note: This product is intended for laboratory research and scientific investigation purposes only. Not for human consumption or veterinary use.
Usage Guidelines
PE 22-28 is supplied as a sterile lyophilized powder and must be reconstituted with bacteriostatic water prior to research use. For optimal stability, gently swirl the vial after adding the diluent—do not shake vigorously. Standard research protocols involve reconstituting the 10mg peptide with 2-4mL of bacteriostatic water, yielding a concentration of 2.5-5mg/mL. Typical research dosing ranges from 0.1-0.5mg per administration, often administered daily or every other day via subcutaneous injection or intranasal route. Due to its role in TREK-1 inhibition, dosing protocols vary based on research objectives. It is recommended to store the reconstituted peptide in a refrigerator (2-8°C) and use within 30 days to maintain peptide integrity.
For researchers investigating comprehensive mood, stress, and neurogenesis protocols, combining PE 22-28 with complementary compounds can yield synergistic insights. Consider exploring the following Dragon Pharma products to enhance your research:
- Selank: An anxiolytic peptide studied alongside PE 22-28 for complementary stress and mood research.
- Semax: A nootropic peptide for comparative research on cognitive enhancement and neuroprotection.
- DIHEXA: A neurogenic peptide for comparative research on neurogenesis and cognitive repair mechanisms.